Next generation flow for minimal residual disease and primary immunodeficiencies
Becton Dickinson
Monday 6th February I 11:00 - 13:00
Johannesburg room I Z1.D10
Overview
This workshop will explore Next Generation Flow™ innovations for Hemato-oncology and Primary Immunodeficiencies. The BD and Cytognos synergy will provide you the biggest advantages on highly sensitive analysis. This will be a practical workshop where you will be able to see standardized live analysis of Multiple Myeloma and B-cell Precursor Acute Lymphoblastic Leukemia Minimal Residual diseases, as well as Primary Immunodeficiency cases.
Learning objectives:
- How standardization improves laboratory efficiency and enables reliable and accurate results for clinical decision and ultimately patient outcome
- Next Generation Flow™ innovations on the study of Primary Immunodeficiencies, Multiple Myeloma and BCP-ALL Minimal Residual Diseases
- The importance of multidimensional tools in the analysis of rare populations
- Automated identification of populations based on immunophenotype
Company bio
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn and Twitter
Presenters
Arantxa Huarriz Sagüés
International Scientific and Clinical Application Specialist
BD-Cytognos S.L.
Arantxa Huarriz works as an International Scientific and Clinical Application Specialist at BD-Cytognos, responsible for customer support and troubleshooting in flow cytometry applications. She performed her Biochemical degree at the University of Pamplona (Spain), followed by a Master in Immunological Research. In 2018, she joined Cytognos S.L. where she earned a scholarship for a Diploma in Flow Cytometry for the diagnosis and monitoring of hematological malignancies and primary immunodeficiencies in the University of Salamanca (Spain).
Engineer Carina Cabrita
Cytognos Product Manager
Carina Cabrita performed her degree and Masters in Biotechnology Engineering in the University of Algarve, Portugal. In 2011, she joined Cytognos, a biotech company specialized in providing flow cytometry solutions (reagents and software) for the evaluation of hematological and immunology diseases. She held different positions with increased responsibilities and since 2015 has performed the role of multiple myeloma and primary immunodeficiencies product manager.
